Multiple Manufacturers

IRESSA

Manufacturer:

Multiple Manufacturers

Iressa HCPCS:

J8565

HCPCS Code Descriptor:

Gefitinib, oral, 250 mg

Category:

J Code

Iressa NDCs:

00310-0482-30, 69339-0168-03, 50742-0366-30, 60505-4512-03

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Package Type:

Not Found

Route of Administration:

Oral

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00310-0482-30

About Iressa:

IRESSA is a medication manufactured by multiple manufacturers and aligned to the J Code: J8565. IRESSA is administered via the oral route of administration.

IRESSA is a cancer medication that belongs to the class of drugs known as antineoplastic epidermal growth factor inhibitor. It works by slowing down and stopping the growth of cancer cells by blocking the epidermal growth factor protein. IRESSA is often used to treat certain types of lung cancer. This drug is manufactured by Astrazeneca and is aligned to the HCPCS code J8565. IRESSA has aligned to the HCPCS code since January 2015 and is still aligned to this code.

ACCESS PRICING AND MORE BY REGISTERING

J8565 Added Date:

January 1, 2005

J8565 Effective Date:

January 1, 2015

J8565 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Iressa billing and coding information.
Our team did not identify a source for Iressa patient assistance information. Please reach out to our team if you feel that this is a mistake.
IRESSA prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for IRESSA. Please check back in a few weeks.